Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Myriad Genetics, Inc. (NasdaqNM:MYGN)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials | Reports
Recent Events
Aug 21Earnings Announcement
Location
320 Wakara Way
Salt Lake City, UT 84108
Phone: (801) 584-3600
Fax: (801) 584-3640
Email: investor@myriad.com
Employees (last reported count): 338
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Investor Relations
 ·Employment
 ·Products & Services
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 26%
·Over the last 6 months:
 · one insider buy; 4,000  shares
 · 9 insider sells; 151.0K shares
  (2.4% of insider shares)
·Institutional: 67% (90% of float)
(288 institutions)
·Net Inst. Buying: 761.0K shares (+4.68%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Myriad Genetics, Inc. engages in the use of gene-based medicine to develop novel therapeutic and molecular diagnostic products. The Company focuses on the emerging field of proteomics, which involves establishing the relationship between protein function and particular diseases by identifying disease-specific proteins. Myriad employs a variety of proprietary proteomic technologies to discover important disease genes and to understand the role these genes and their related proteins play in the onset and progression of disease. Using proprietary technologies, the Company identified 22 drug targets to date. Myriad delivered 13 of these drug targets to its strategic partners based on its discovery of genes involved in breast cancer, brain cancer, prostate cancer, heart disease, dementia and other disorders. Partners include Bayer Corporation, Eli Lilly and Company, Hitachi Ltd., Hoffmann-LaRoche Inc., Pharmacia Corporation, Novartis Corporation, Schering-Plough Corporation and Schering AG.
More from Market Guide: Expanded Business Description

Financial Summary
MYGN is engaged in the discovery and sequencing of genes related to major common diseases. MYGN operates a genetic predisposition testing lab and develops products to prevent or treat the diseases associated with these genes. For the nine months ended 3/31/01, revenues increased 38% to $34.3 million. Net loss fell 19% to $5 million. Revenues reflect increased research revenue from strategic alliances. Lower loss benefitted from increased interest income.

Recent Earnings Announcement
For the 3 months ended 06/30/2001, revenues were 10,822; after tax earnings were -2,187. (Preliminary; reported in thousands of dollars.)

More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Hugh D'Andrade
Chairman
--  --  
Peter Meldrum, 53
Pres, CEO,
$426K$5.8M
Walter Gilbert, Ph.D., 68
Vice Chairman
--  --  
Jay Moyes, 46
CFO and VP of Fin.
234K1.8M
Gregory Critchfield, M.D., 49
Pres of Myriad Genetic Laboratories, Inc.
330K1.3M
Dollar amounts are as of 30-June-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:MYGNAs of 31-Aug-2001
Price and Volume
52-Week Low
on 4-Apr-2001
$29.50 
Recent Price$43.60 
52-Week High
on 6-Nov-2000
$138.00 
Beta0.52 
Daily Volume (3-month avg)732.8K
Daily Volume (10-day avg)697.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-43.0%
52-Week Change
relative to S&P500
-23.5%
Share-Related Items
Market Capitalization$1.01B
Shares Outstanding23.3M
Float17.2M
Dividends & Splits
Annual Dividendnone 
Last Split: 2 for 1 on 12-Sep-2000
Per-Share Data
Book Value (mrq*)$5.99 
Earnings (ttm)-$0.31 
Earnings (mrq)-$0.09 
Sales (ttm)$1.96 
Cash (mrq*)$5.50 
Valuation Ratios
Price/Book (mrq*)7.28 
Price/EarningsN/A 
Price/Sales (ttm)22.27 
Income Statements
Sales (ttm)$45.2M
EBITDA (ttm*)-$9.55M
Income available to common (ttm)-$7.17M
Profitability
Profit Margin (ttm)-15.9%
Operating Margin (ttm)-30.3%
Fiscal Year
Fiscal Year EndsJune 30
Most recent quarter
(fully updated)
31-Mar-2001
Most recent quarter
(flash earnings)
30-June-2001
Management Effectiveness
Return on Assets (ttm)-5.20%
Return on Equity (ttm)-6.31%
Financial Strength
Current Ratio (mrq*)5.80 
Debt/Equity (mrq*)0 
Total Cash (mrq)$146.0M
Short Interest
As of 8-Aug-2001
Shares Short694.0K
Percent of Float4.0%
Shares Short
(Prior Month)
1.02M
Short Ratio1.05 
Daily Volume662.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   B = billions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001, except mrq*/ttm* items as of 31-Mar-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.